CN117186199A - Beta 2-microglobulin blocking peptide, pharmaceutical composition and application thereof - Google Patents
Beta 2-microglobulin blocking peptide, pharmaceutical composition and application thereof Download PDFInfo
- Publication number
- CN117186199A CN117186199A CN202210609077.3A CN202210609077A CN117186199A CN 117186199 A CN117186199 A CN 117186199A CN 202210609077 A CN202210609077 A CN 202210609077A CN 117186199 A CN117186199 A CN 117186199A
- Authority
- CN
- China
- Prior art keywords
- abeta
- brain
- polypeptide
- seq
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 105
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
- 102000015736 beta 2-Microglobulin Human genes 0.000 title abstract description 129
- 108010081355 beta 2-Microglobulin Proteins 0.000 title abstract description 129
- 230000000903 blocking effect Effects 0.000 title abstract description 33
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 60
- 229920001184 polypeptide Polymers 0.000 claims abstract description 42
- 239000012634 fragment Substances 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 12
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims description 45
- 208000024827 Alzheimer disease Diseases 0.000 claims description 37
- 208000037259 Amyloid Plaque Diseases 0.000 claims description 20
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 19
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 19
- 230000005764 inhibitory process Effects 0.000 claims description 15
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 5
- 108091033319 polynucleotide Proteins 0.000 claims description 5
- 239000002157 polynucleotide Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 231100000189 neurotoxic Toxicity 0.000 claims description 4
- 230000002887 neurotoxic effect Effects 0.000 claims description 4
- 238000003259 recombinant expression Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000003606 oligomerizing effect Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 235000014304 histidine Nutrition 0.000 claims description 2
- 150000002411 histidines Chemical group 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 abstract description 4
- 208000028698 Cognitive impairment Diseases 0.000 abstract description 3
- 210000004556 brain Anatomy 0.000 description 49
- 241000699670 Mus sp. Species 0.000 description 26
- 238000006384 oligomerization reaction Methods 0.000 description 25
- 210000005013 brain tissue Anatomy 0.000 description 22
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 14
- 206010029350 Neurotoxicity Diseases 0.000 description 12
- 206010044221 Toxic encephalopathy Diseases 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 231100000228 neurotoxicity Toxicity 0.000 description 12
- 230000007135 neurotoxicity Effects 0.000 description 12
- 238000000151 deposition Methods 0.000 description 11
- 230000008021 deposition Effects 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- UCNNZELZXFXXJQ-BZSNNMDCSA-N Leu-Leu-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 UCNNZELZXFXXJQ-BZSNNMDCSA-N 0.000 description 9
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 9
- ZKBKUWQVDWWSRI-BZSNNMDCSA-N Ser-Phe-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZKBKUWQVDWWSRI-BZSNNMDCSA-N 0.000 description 9
- LVFZXRQQQDTBQH-IRIUXVKKSA-N Tyr-Thr-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O LVFZXRQQQDTBQH-IRIUXVKKSA-N 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 238000011533 pre-incubation Methods 0.000 description 9
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 8
- 210000001320 hippocampus Anatomy 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- SHUFSZDAIPLZLF-BEAPCOKYSA-N Phe-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N)O SHUFSZDAIPLZLF-BEAPCOKYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 5
- 238000000749 co-immunoprecipitation Methods 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 238000003119 immunoblot Methods 0.000 description 5
- 238000003125 immunofluorescent labeling Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000007351 Aβ plaque formation Effects 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 102000047279 human B2M Human genes 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- HJOSVGCWOTYJFG-WDCWCFNPSA-N Thr-Glu-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N)O HJOSVGCWOTYJFG-WDCWCFNPSA-N 0.000 description 3
- 230000006933 amyloid-beta aggregation Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 3
- 229960002327 chloral hydrate Drugs 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000000971 hippocampal effect Effects 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 238000007427 paired t-test Methods 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 2
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 2
- AGVNTAUPLWIQEN-ZPFDUUQYSA-N Arg-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AGVNTAUPLWIQEN-ZPFDUUQYSA-N 0.000 description 2
- ZJBUILVYSXQNSW-YTWAJWBKSA-N Arg-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O ZJBUILVYSXQNSW-YTWAJWBKSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- MFORDNZDKAVNSR-SRVKXCTJSA-N Gln-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCC(N)=O MFORDNZDKAVNSR-SRVKXCTJSA-N 0.000 description 2
- STGQSBKUYSPPIG-CIUDSAMLSA-N His-Ser-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 STGQSBKUYSPPIG-CIUDSAMLSA-N 0.000 description 2
- IWMJFLJQHIDZQW-KKUMJFAQSA-N Leu-Ser-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IWMJFLJQHIDZQW-KKUMJFAQSA-N 0.000 description 2
- OJDFAABAHBPVTH-MNXVOIDGSA-N Lys-Ile-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O OJDFAABAHBPVTH-MNXVOIDGSA-N 0.000 description 2
- UGCIQUYEJIEHKX-GVXVVHGQSA-N Lys-Val-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O UGCIQUYEJIEHKX-GVXVVHGQSA-N 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 2
- 238000010220 Pearson correlation analysis Methods 0.000 description 2
- PPNPDKGQRFSCAC-CIUDSAMLSA-N Ser-Lys-Asp Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(O)=O)C(O)=O PPNPDKGQRFSCAC-CIUDSAMLSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003941 amyloidogenesis Effects 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 210000004507 artificial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 108010085325 histidylproline Proteins 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 108010003700 lysyl aspartic acid Proteins 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
- 230000003959 neuroinflammation Effects 0.000 description 2
- 230000009689 neuronal regeneration Effects 0.000 description 2
- 208000003154 papilloma Diseases 0.000 description 2
- 108010051242 phenylalanylserine Proteins 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- 108010079202 tyrosyl-alanyl-cysteine Proteins 0.000 description 2
- 101150029062 15 gene Proteins 0.000 description 1
- IFKQPMZRDQZSHI-GHCJXIJMSA-N Ala-Ile-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O IFKQPMZRDQZSHI-GHCJXIJMSA-N 0.000 description 1
- GSHKMNKPMLXSQW-KBIXCLLPSA-N Ala-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C)N GSHKMNKPMLXSQW-KBIXCLLPSA-N 0.000 description 1
- 238000010173 Alzheimer-disease mouse model Methods 0.000 description 1
- 101100502320 Arabidopsis thaliana FAD4 gene Proteins 0.000 description 1
- HJAICMSAKODKRF-GUBZILKMSA-N Arg-Cys-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O HJAICMSAKODKRF-GUBZILKMSA-N 0.000 description 1
- PSUXEQYPYZLNER-QXEWZRGKSA-N Arg-Val-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O PSUXEQYPYZLNER-QXEWZRGKSA-N 0.000 description 1
- OPEPUCYIGFEGSW-WDSKDSINSA-N Asn-Gly-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O OPEPUCYIGFEGSW-WDSKDSINSA-N 0.000 description 1
- OLVIPTLKNSAYRJ-YUMQZZPRSA-N Asn-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N OLVIPTLKNSAYRJ-YUMQZZPRSA-N 0.000 description 1
- UYXXMIZGHYKYAT-NHCYSSNCSA-N Asn-His-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC(=O)N)N UYXXMIZGHYKYAT-NHCYSSNCSA-N 0.000 description 1
- BYLSYQASFJJBCL-DCAQKATOSA-N Asn-Pro-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O BYLSYQASFJJBCL-DCAQKATOSA-N 0.000 description 1
- XEDQMTWEYFBOIK-ACZMJKKPSA-N Asp-Ala-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O XEDQMTWEYFBOIK-ACZMJKKPSA-N 0.000 description 1
- ZLGKHJHFYSRUBH-FXQIFTODSA-N Asp-Arg-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLGKHJHFYSRUBH-FXQIFTODSA-N 0.000 description 1
- UJGRZQYSNYTCAX-SRVKXCTJSA-N Asp-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UJGRZQYSNYTCAX-SRVKXCTJSA-N 0.000 description 1
- UMHUHHJMEXNSIV-CIUDSAMLSA-N Asp-Leu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UMHUHHJMEXNSIV-CIUDSAMLSA-N 0.000 description 1
- KGHLGJAXYSVNJP-WHFBIAKZSA-N Asp-Ser-Gly Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O KGHLGJAXYSVNJP-WHFBIAKZSA-N 0.000 description 1
- XWKPSMRPIKKDDU-RCOVLWMOSA-N Asp-Val-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O XWKPSMRPIKKDDU-RCOVLWMOSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- XGIAHEUULGOZHH-GUBZILKMSA-N Cys-Arg-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)N XGIAHEUULGOZHH-GUBZILKMSA-N 0.000 description 1
- ZOMMHASZJQRLFS-IHRRRGAJSA-N Cys-Tyr-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CS)N ZOMMHASZJQRLFS-IHRRRGAJSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- CKRUHITYRFNUKW-WDSKDSINSA-N Glu-Asn-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O CKRUHITYRFNUKW-WDSKDSINSA-N 0.000 description 1
- HVKAAUOFFTUSAA-XDTLVQLUSA-N Glu-Tyr-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O HVKAAUOFFTUSAA-XDTLVQLUSA-N 0.000 description 1
- YPHPEHMXOYTEQG-LAEOZQHASA-N Glu-Val-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCC(O)=O YPHPEHMXOYTEQG-LAEOZQHASA-N 0.000 description 1
- HQTDNEZTGZUWSY-XVKPBYJWSA-N Glu-Val-Gly Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)CCC(O)=O)C(=O)NCC(O)=O HQTDNEZTGZUWSY-XVKPBYJWSA-N 0.000 description 1
- YMUFWNJHVPQNQD-ZKWXMUAHSA-N Gly-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN YMUFWNJHVPQNQD-ZKWXMUAHSA-N 0.000 description 1
- ULZCYBYDTUMHNF-IUCAKERBSA-N Gly-Leu-Glu Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ULZCYBYDTUMHNF-IUCAKERBSA-N 0.000 description 1
- DHNXGWVNLFPOMQ-KBPBESRZSA-N Gly-Phe-His Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)NC(=O)CN DHNXGWVNLFPOMQ-KBPBESRZSA-N 0.000 description 1
- RVKIPWVMZANZLI-UHFFFAOYSA-N H-Lys-Trp-OH Natural products C1=CC=C2C(CC(NC(=O)C(N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-UHFFFAOYSA-N 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- RXVOMIADLXPJGW-GUBZILKMSA-N His-Asp-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O RXVOMIADLXPJGW-GUBZILKMSA-N 0.000 description 1
- FLYSHWAAHYNKRT-JYJNAYRXSA-N His-Gln-Phe Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O FLYSHWAAHYNKRT-JYJNAYRXSA-N 0.000 description 1
- IDQNVIWPPWAFSY-AVGNSLFASA-N His-His-Gln Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(N)=O)C(O)=O IDQNVIWPPWAFSY-AVGNSLFASA-N 0.000 description 1
- BZKDJRSZWLPJNI-SRVKXCTJSA-N His-His-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O BZKDJRSZWLPJNI-SRVKXCTJSA-N 0.000 description 1
- WJGSTIMGSIWHJX-HVTMNAMFSA-N His-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N WJGSTIMGSIWHJX-HVTMNAMFSA-N 0.000 description 1
- ZVKDCQVQTGYBQT-LSJOCFKGSA-N His-Pro-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O ZVKDCQVQTGYBQT-LSJOCFKGSA-N 0.000 description 1
- YEKYGQZUBCRNGH-DCAQKATOSA-N His-Pro-Ser Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC2=CN=CN2)N)C(=O)N[C@@H](CO)C(=O)O YEKYGQZUBCRNGH-DCAQKATOSA-N 0.000 description 1
- BCSGDNGNHKBRRJ-ULQDDVLXSA-N His-Tyr-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CN=CN2)N BCSGDNGNHKBRRJ-ULQDDVLXSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- WUKLZPHVWAMZQV-UKJIMTQDSA-N Ile-Glu-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)O)N WUKLZPHVWAMZQV-UKJIMTQDSA-N 0.000 description 1
- NJGXXYLPDMMFJB-XUXIUFHCSA-N Ile-Val-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N NJGXXYLPDMMFJB-XUXIUFHCSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- BAJIJEGGUYXZGC-CIUDSAMLSA-N Leu-Asn-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N BAJIJEGGUYXZGC-CIUDSAMLSA-N 0.000 description 1
- LXKNSJLSGPNHSK-KKUMJFAQSA-N Leu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N LXKNSJLSGPNHSK-KKUMJFAQSA-N 0.000 description 1
- XOEDPXDZJHBQIX-ULQDDVLXSA-N Leu-Val-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XOEDPXDZJHBQIX-ULQDDVLXSA-N 0.000 description 1
- HQVDJTYKCMIWJP-YUMQZZPRSA-N Lys-Asn-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O HQVDJTYKCMIWJP-YUMQZZPRSA-N 0.000 description 1
- NCTDKZKNBDZDOL-GARJFASQSA-N Lys-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N)C(=O)O NCTDKZKNBDZDOL-GARJFASQSA-N 0.000 description 1
- GHKXHCMRAUYLBS-CIUDSAMLSA-N Lys-Ser-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O GHKXHCMRAUYLBS-CIUDSAMLSA-N 0.000 description 1
- JOSAKOKSPXROGQ-BJDJZHNGSA-N Lys-Ser-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JOSAKOKSPXROGQ-BJDJZHNGSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100040243 Microtubule-associated protein tau Human genes 0.000 description 1
- 101710115937 Microtubule-associated protein tau Proteins 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- CYZBFPYMSJGBRL-DRZSPHRISA-N Phe-Ala-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O CYZBFPYMSJGBRL-DRZSPHRISA-N 0.000 description 1
- MQWISMJKHOUEMW-ULQDDVLXSA-N Phe-Arg-His Chemical compound C([C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CC=CC=C1 MQWISMJKHOUEMW-ULQDDVLXSA-N 0.000 description 1
- KBVJZCVLQWCJQN-KKUMJFAQSA-N Phe-Leu-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O KBVJZCVLQWCJQN-KKUMJFAQSA-N 0.000 description 1
- IPFXYNKCXYGSSV-KKUMJFAQSA-N Phe-Ser-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N IPFXYNKCXYGSSV-KKUMJFAQSA-N 0.000 description 1
- IWNOFCGBMSFTBC-CIUDSAMLSA-N Pro-Ala-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IWNOFCGBMSFTBC-CIUDSAMLSA-N 0.000 description 1
- GMJDSFYVTAMIBF-FXQIFTODSA-N Pro-Ser-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GMJDSFYVTAMIBF-FXQIFTODSA-N 0.000 description 1
- VQBLHWSPVYYZTB-DCAQKATOSA-N Ser-Arg-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)N VQBLHWSPVYYZTB-DCAQKATOSA-N 0.000 description 1
- VGNYHOBZJKWRGI-CIUDSAMLSA-N Ser-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO VGNYHOBZJKWRGI-CIUDSAMLSA-N 0.000 description 1
- KAAPNMOKUUPKOE-SRVKXCTJSA-N Ser-Asn-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KAAPNMOKUUPKOE-SRVKXCTJSA-N 0.000 description 1
- JFWDJFULOLKQFY-QWRGUYRKSA-N Ser-Gly-Phe Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JFWDJFULOLKQFY-QWRGUYRKSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- CYCGARJWIQWPQM-YJRXYDGGSA-N Thr-Tyr-Ser Chemical compound C[C@@H](O)[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CO)C([O-])=O)CC1=CC=C(O)C=C1 CYCGARJWIQWPQM-YJRXYDGGSA-N 0.000 description 1
- GKUROEIXVURAAO-BPUTZDHNSA-N Trp-Asp-Arg Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GKUROEIXVURAAO-BPUTZDHNSA-N 0.000 description 1
- QJBWZNTWJSZUOY-UWJYBYFXSA-N Tyr-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N QJBWZNTWJSZUOY-UWJYBYFXSA-N 0.000 description 1
- UNUZEBFXGWVAOP-DZKIICNBSA-N Tyr-Glu-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UNUZEBFXGWVAOP-DZKIICNBSA-N 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- PHZGFLFMGLXCFG-FHWLQOOXSA-N Val-Lys-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N PHZGFLFMGLXCFG-FHWLQOOXSA-N 0.000 description 1
- IECQJCJNPJVUSB-IHRRRGAJSA-N Val-Tyr-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(O)=O IECQJCJNPJVUSB-IHRRRGAJSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000013629 beta-amyloid clearance Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000036749 excitatory postsynaptic potential Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108010008237 glutamyl-valyl-glycine Proteins 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 108010087823 glycyltyrosine Proteins 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 208000018628 immunodeficiency 43 Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000012301 transgenic model Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention belongs to the field of biological medicine, and relates to a beta 2-microglobulin blocking peptide, a pharmaceutical composition and application thereof. In particular, the invention relates to an isolated polypeptide which is a polypeptide shown in SEQ ID NO. 3 or a truncated fragment of the polypeptide shown in SEQ ID NO. 3, wherein the truncated fragment comprises the polypeptide shown in SEQ ID NO. 8. The isolated polypeptide can effectively prevent and treat AD or cognitive impairment caused by AD, and has good application prospect.
Description
Technical Field
The invention belongs to the field of biological medicine, and relates to a beta 2-microglobulin blocking peptide, a pharmaceutical composition and application thereof.
Background
Alzheimer's Disease (AD) is one of the most common neurodegenerative diseases in humans, and according to the 2018 report of Alzheimer's disease in the world, 5000 tens of thousands of people worldwide have AD by 2050, a figure that will increase to 1.52 billion. The main pathological features of the disease include amyloid deposition formed by oligomerization of beta-amyloid (aβ) produced by cleavage of brain amyloid precursor protein (Amyloid precursor protein, APP), neurofibrillary tangles (Neurofibrillary tangles, NFTs) formed by aggregation after abnormal phosphorylation of intracellular microtubule-associated protein tau, neuronal loss and excessive neuroinflammation, and the like. The clinical manifestations of AD patients are mainly memory decline and cognitive impairment, and this decline worsens with the progression of the disease, eventually losing all memory and life self-ability until death. In view of the advent of global aging, together with the continued rise in the incidence of AD, and the current lack of effective therapeutic measures, AD is one of the diseases that severely threatens human health.
Since AD was found in 1901, there has been considerable research on its pathogenesis, however, no clear definition exists at present. The "Abeta cascade hypothesis" is one of the main theories of the pathogenesis of AD, which considers that Abeta produced by aberrant cleavage of APP is neurotoxic 1-40/42 Plays a central role in the pathogenesis of AD and is a common pathway for the induction of AD for various reasons. A series of neurotoxic reactions caused by Abeta oligomers can excite neuroinflammation, lead to nerve cell dysfunction and neuron loss, and finally cause dementia. Thus, reduction of aβ production in the brain, promotion of aβ clearance, inhibition of aβ aggregation, and reduction of neurotoxicity have become one of the main measures for the treatment of AD.
Beta 2-microglobulin (B2M) is a senescence-promoting factor which has been recently receiving a great deal of attention, and B2M is a constituent subunit of the major histocompatibility complex I (Major histocompatibility complex I, MHC-I), encoded by the human chromosome 15 gene, comprising 119 amino acids. Since B2M is not anchored to the cell membrane by a transmembrane domain, B2M can be released from the MHC-I complex into the cell gap. Normally, B2M proteins exist in soluble monomeric form, but under the influence of some pathological factors, B2M aggregates and deposits. These pathological factors include aging, long-term renal dysfunction, inflammation, and the like. B2M amyloid deposition is mainly present in the osteoarticular area and ultimately leads to severe arthritis, fractures and carpal tunnel syndrome. In addition, in many disease states, there is an increase in B2M in both serum and plasma, of particular concern is that both plasma and cerebrospinal fluid in AD patients are significantly higher in B2M than in normal cohort controls. Brain stereotactic injection of B2M inhibits neuronal regeneration and impairs cognitive function in mice, whereas B2M deficiency promotes neuronal regeneration and reverses age-related cognitive dysfunction. However, whether B2M has direct or indirect influence on the occurrence and development of AD diseases is not reported.
Disclosure of Invention
The inventors have conducted intensive studies and inventive efforts to find out the role of B2M in the development of AD, and have surprisingly found that B2M and Abeta are hindered 1-42 The bound blocking peptides have potential as drugs for the prevention and treatment of AD, particularly cognitive impairment caused by AD. The following invention is thus provided:
one aspect of the invention relates to an isolated polypeptide which is a polypeptide as set forth in SEQ ID NO. 3 or a truncated fragment of a polypeptide as set forth in SEQ ID NO. 3, wherein the truncated fragment comprises a polypeptide as set forth in SEQ ID NO. 8.
In some embodiments of the invention, the isolated polypeptide, wherein the truncated fragment does not comprise the 6 histidines at the N-terminus of the polypeptide shown in SEQ ID NO. 3.
In some embodiments of the invention, the isolated polypeptide is a polypeptide as set forth in any one of SEQ ID NOs 7-8.
HHHHHHHSDLSFSKDWSFYLLYYTEFTPTEK(SEQ ID NO:3)
SFYLLYYTEFTPTEK(SEQ ID NO:7)
SFYLLYYTE(SEQ ID NO:8)
In some embodiments of the invention, the isolated polypeptide is a polypeptide as set forth in any one of SEQ ID NOs 11-15.
SFYLLYYTEFTPTE(SEQ ID NO:11)
SFYLLYYTEFTPT(SEQ ID NO:12)
SFYLLYYTEFTP(SEQ ID NO:13)
SFYLLYYTEFT(SEQ ID NO:14)
SFYLLYYTEF(SEQ ID NO:15)
Another aspect of the invention relates to an isolated polynucleotide encoding an isolated polypeptide according to any one of the invention.
Yet another aspect of the invention relates to a recombinant expression vector comprising an isolated polynucleotide of the invention.
A further aspect of the invention relates to a transformed cell comprising a recombinant expression vector of the invention.
A further aspect of the invention relates to a pharmaceutical composition comprising an isolated polypeptide according to any one of the invention.
In some embodiments of the invention, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients.
A further aspect of the invention relates to the use of an isolated polypeptide according to any one of the invention for the manufacture of a medicament for the treatment or prevention of alzheimer's disease.
A further aspect of the invention relates to the use of an isolated polypeptide according to any of the invention for the preparation of a medicament as follows:
inhibition of B2M-induced Abeta 1-42 Oligomerizing agents, agents inhibiting B2M-induced formation of beta-amyloid plaques or inhibiting aβ 1-42 Is a neurotoxic drug.
The invention discovers that the expression of B2M in brain tissue of AD patients is obviously increased for the first time, and the expression level of B2M in brain and Abeta 1-42 There is a significant positive correlation between levels, and further increasing B2M levels in AD mouse model (5 x FAD) brains by brain stereotactic injection can increase β -amyloid plaque deposition in 5 x FAD mice. Further, the present inventors found that B2M and Abeta 1-42 Direct interactions exist and B2M and Abeta can be inhibited by using truncated B2M amino acid sequence as blocking peptide 1-42 Aggregation, inhibition of B2M and Abeta 1-42 Neurotoxicity, in vivo experiments show that the blocking peptide can obviously inhibit B2M to Abeta in brain 1-42 Promoting aggregation, and reducing beta-amyloid plaque deposition in brain. The discovery provides a potential drug target point and a new therapeutic mode based on the target point for clinical treatment of AD.
An isolated polypeptide according to any one of the present invention for use in the treatment or prevention of alzheimer's disease.
An isolated polypeptide according to any one of the present invention for use in inhibiting B2M-induced aβ 1-42 Oligomerization and inhibition of B2M-induced betaAmyloid plaque formation or for inhibition of aβ 1-42 Is a neurotoxicity of (a).
A further aspect of the invention relates to a method for the treatment or prevention of alzheimer's disease comprising the step of administering to a subject in need thereof an effective amount of an isolated polypeptide according to any of the invention.
In yet another aspect, the invention relates to a method of inhibiting B2M-induced Abeta 1-42 Oligomerization or inhibition of B2M-induced beta-amyloid plaques or inhibition of Abeta 1-42 Comprising the step of administering to a subject in need thereof an effective amount of an isolated polypeptide of any one of the present invention.
In some embodiments of the invention, the amino acid sequence of the beta 2-microglobulin is shown in SEQ ID NO 9.
The amino acid sequence (N-to C-terminus) of the human B2M protein is as follows:
MSRSVALAVLALLSLSGLEAIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDM(SEQ ID NO:9)
in the present invention, when referring to the amino acid sequence of β2-microglobulin (B2M), it includes the full length of β2-microglobulin, and also includes fusion proteins thereof. However, it is understood by those skilled in the art that mutations or variations (including but not limited to substitutions, deletions and/or additions) may be naturally occurring or artificially introduced in the amino acid sequence of the β2-microglobulin without affecting its biological function. In one embodiment of the invention, the beta 2-microglobulin is a human beta 2-microglobulin. In one embodiment of the invention, the amino acid sequence of the beta 2-microglobulin is shown in SEQ ID NO 9.
In the present invention, the term "host cell" refers to a cell into which a vector is introduced, and includes many cell types such as prokaryotic cells such as E.coli or Bacillus subtilis, fungal cells such as yeast cells or Aspergillus, insect cells such as S2 drosophila cells or Sf9, or animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, heLa cells, BHK cells, HEK 293 cells, or human cells.
In the present invention, the term "vector" refers to a nucleic acid vehicle into which a polynucleotide that inhibits a protein can be inserted. For example, the carrier comprises: a plasmid; phagemid; a cosmid; artificial chromosomes such as Yeast Artificial Chromosome (YAC), bacterial Artificial Chromosome (BAC) or P1-derived artificial chromosome (PAC); phages such as lambda phage or M13 phage, animal viruses, etc. Animal virus species used as vectors are retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpesviruses (e.g., herpes simplex viruses), poxviruses, baculoviruses, papillomaviruses, papilloma-virus-papilloma-vacuolated viruses (e.g., SV 40). One vector may contain a variety of elements that control expression.
The term "disease and/or disorder" refers to a physical state of the subject that is associated with the disease and/or disorder of the present invention.
The term "subject" may refer to a patient or other animal, particularly a mammal, such as a human, dog, monkey, cow, horse, etc., receiving a pharmaceutical composition of the invention to treat, prevent, ameliorate and/or alleviate a disease or disorder described herein.
The term "blocking peptide" refers to a polypeptide that is capable of competitively binding aβ with a full length B2M protein, thereby inhibiting the biological effect of B2M binding aβ that promotes oligomerization of aβ.
In the present invention, if not specified, the concentration unit/. Mu.M represents/. Mu.mol/L, mM represents mmol/L, and nM represents nmol/L.
In the present invention, when the amount of drug to be added to cells is mentioned, it is generally referred to as the final concentration of the drug after the drug is added unless otherwise specified.
Aβ 1-42 The amino acid sequence of (2) is as follows:
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA(SEQ ID NO:10)
advantageous effects of the invention
The invention achieves one or more of the following technical effects (1) - (4):
(1) The polypeptide of the present invention can effectively prevent and/or treat Alzheimer's disease.
(2) The polypeptide of the invention canCan effectively inhibit B2M induced Abeta 1-42 Oligomerization.
(3) The polypeptide of the invention can effectively inhibit the formation of B2M-induced beta-amyloid plaques.
(4) The polypeptide of the invention can effectively inhibit Abeta 1-42 Is a neurotoxicity of (a).
Drawings
Fig. 1A to 1B: the B2M expression level in the brain of AD patients was significantly increased. Wherein:
fig. 1A: the B2M expression immunoblotting detection result in the cerebral cortex tissue of the AD patient.
Fig. 1B: image J analyzed B2M expression levels in fig. 1A, control group n=8 human brain tissues, AD group n=21 human brain tissues. The data were statistically analyzed using student t test. ns, no significant difference, P >0.05; * P <0.05; * P <0.01; * P <0.001.
Fig. 1C: through Abeta 1-42 ELISA detected Abeta in the 29 human brain tissues 1-42 Level, abeta in human brain was found by Pearson correlation analysis 1-42 There is a significant positive correlation between levels and B2M expression levels in the human brain.
FIGS. 1D-1F increasing B2M levels in the brain of 5 XFAD mice promotes amyloid plaque deposition in the brain. Mice were anesthetized with 5% chloral hydrate after 2 months by brain stereotactic injection into the hippocampus of 4 month old 5×fad mice with 1 μl (1 μg/μl) of purified B2M protein or 1 μl PBS (control per mouse brain), heart perfused with phosphate buffer, brain tissue was taken, fixed overnight in 4% paraformaldehyde, dehydrated with 25% and 30% sucrose solution, brain tissue embedded with OCT, frozen sections were post immunofluorescent staining, dye 4',6-diamidino-2-phenylindole (DAPI) labeled nuclei, antibody 6E10 labeled aβ, and images were acquired by laser confocal fluorescence microscopy. Scale, 300 μm. Data represent mean ± standard error. Wherein:
fig. 1D: immunofluorescent staining of 5×fad mice brain tissue amyloid plaques. N=6 mice per group. Wherein the dashed box indicates the hippocampal DG area range, and also represents the brain tissue area where the statistical plaque is located.
Fig. 1E: FIG. 1D shows the statistics of the Number of β -amyloid plaques (Number of Abeta depositions) in the hippocampus DG region. The data were statistically analyzed using a Paired t test. ns, no significant difference, P >0.05; * P <0.05; * P <0.01; * P <0.001.
Fig. 1F: FIG. 1D shows statistics of the Area of β -amyloid plaques (Area of Abeta depositions) in the hippocampus DG region. The data were statistically analyzed using a Paired t test. ns, no significant difference, P >0.05; * P <0.05; * P <0.01; * P <0.001.
Fig. 2A to 2B: in vitro purified B2M protein and purified aβ 1-42 Co-immunoprecipitation (co-IP) experiments of interactions between proteins. Wherein:
fig. 2A: immunoprecipitation of Abeta with antibodies against Abeta 1-42 And B2M.
Fig. 2B: immunoprecipitation of B2M and Abeta with anti-B2M antibodies 1-42 。
Fig. 2C: in vivo B2M and Abeta using 5 XFAD mouse brain tissue 1-42 As a result of co-IP experiment of the interaction, the antibody used was an anti-Abeta antibody.
Fig. 2D: incubation of Abeta with B2M in vitro with thioflavin-T indicator 1-42 Post-promotion of Aβ 1-42 The result of continuous detection by the oligomerized fluorescent enzyme label instrument. At 37 ℃, different concentrations of full-length B2M protein and Abeta 1-42 Co-incubating, adding thioflavin-T into the experimental system, and detecting the change of a thioflavin-T fluorescent signal value every 5min under the conditions of excitation light wavelength lambda=448 nm and absorption light wavelength lambda=488 nm by using a fluorescence microplate reader. And (5) drawing a graph of the change of the fluorescence signal value with time after the test is finished. Data represent the average of absolute fluorescence signal intensities.
Fig. 2E: thioflavin-T fluorescence detection results for B2M protein at corresponding concentrations under the same experimental conditions as in fig. 2D. Data represent the average of absolute fluorescence signal intensities.
Fig. 3A: segment schematic of a short peptide with a B2M amino acid full-length sequence truncated to 4 non-overlapping sequences.
Fig. 3B: truncated B2M small peptides inhibit B2M promotionAβ 1-42 Experimental results of oligomerized thioflavin-T. Truncated B2M amino acid sequence as blocking peptide and Abeta 1-42 Preincubation at 37℃for 3 hours followed by further addition of full length B2M protein and continued incubation of Abeta 1-42 Analysis of blocking peptides to promote Aβ to B2M by analysis of changes in thioflavin-T fluorescence signal intensity 1-42 Oligomerization inhibition effect. Data represent the average of absolute fluorescence signal intensities.
Fig. 3C: detection of B2M-3 blocking peptides at different concentrations for promotion of Abeta by B2M based on the thioflavin-T assay described above 1-42 Inhibition of oligomerization. Data represent the average of absolute fluorescence signal intensities.
Fig. 3D: detection of B2M-3 blocking peptides by Transmission Electron Microscopy (TEM) technique to promote Aβ by blocking B2M 1-42 Oligomerization of Abeta 1-42 Morphological effects of the formed filaments. Scale, 1 μm.
Fig. 3E: to further narrow down the amino acid sequence range that exerts the repressing effect, the present inventors further represented the B2M-3 blocking peptide as a segment schematic of 3 short peptides with no overlapping sequences.
Fig. 3F to 3H: the thioflavin-T experiments described above were performed on 3 further truncated small peptides, and small peptide sequences of different concentrations were analyzed to promote Aβ for B2M 1-42 Inhibition of oligomerization. Data represent the average of absolute fluorescence signal intensities. Wherein:
fig. 3F: three different concentrations of the first B2M-3 truncated small peptide (B2M-3-1) preincubate Abeta 1-42 And 3 hours, then adding full-length B2M protein, and continuously detecting the change condition of the thioflavin-T fluorescent signal based on a fluorescent enzyme-labeled instrument.
Fig. 3G: three different concentrations of the second-stage B2M-3 short-cut small peptide (B2M-3-2) preincubate Abeta 1-42 And 3 hours, then adding full-length B2M protein, and continuously detecting the change condition of the thioflavin-T fluorescent signal based on a fluorescent enzyme-labeled instrument.
Fig. 3H: three different concentrations of the third-stage B2M-3 short-cut small peptide (B2M-3-3) preincubated Abeta 1-42 And 3 hours, then adding full-length B2M protein, and continuously detecting the change condition of the thioflavin-T fluorescent signal based on a fluorescent enzyme-labeled instrument.
Fig. 4A to 4B: B2M-3 blocking peptides promote Aβ to B2M 1-42 In vitro electrophysiological experimental results of the inhibitory effect of neurotoxicity produced by oligomerization. Preincubation of Abeta with B2M-3 blocking peptide or control nonsensical peptide sequence (NS) at 37 ℃ 1-42 3 hours, then adding full-length B2M protein and further incubating for 12 hours to obtain two kinds of oligomerization Abeta with different oligomerization degrees 1-42 The product is obtained. Based on oligomerised Abeta 1-42 With neurotoxicity, the inventor incubates the two kinds of Abeta products (abbreviated as oAbeta) with different oligomerization states respectively for 2 months of in vitro brain slices of wild mice, incubates for 1.5 hours, and then performs electrophysiological long-time-interval enhancement (LTP) experiments to detect the influence of the oAbeta on synaptic plasticity of the in vitro brain slice nerve loops. Wherein, FIG. 4B data was statistically analyzed using one-way ANOVA. ns, no significant difference, P>0.05;*P<0.05;**P<0.01;***P<0.001;****P<0.001. Wherein:
fig. 4A: the analysis results were recorded in the isolated brain slice CA1 region LTP. oaβ -treated groups were n=4 mice per group, and brain numbers n=8 were recorded per group. Control group treated with the single peptide had n=4 mice per group, and brain number n=7 was recorded per group.
Fig. 4B: LTP record in fig. 4A results last 10min fEPSP amplitude statistical analysis. Each set of n values is identical to fig. 4A.
Fig. 4C to 4D: the quantity of beta-amyloid plaque deposition and plaque deposition area in the brain of AD mice are significantly reduced after the 5X FAD mice are injected with the B2M-3 blocking peptide. Wherein, fig. 4C and 4D data were statistically analyzed using a Paired t test. ns, no significant difference, P >0.05; * P <0.05; * P <0.01; * P <0.001. Wherein:
fig. 4C: immunofluorescent staining of β -amyloid plaques deposited in hippocampal DG region in brain of 5×fad mice injected with B2M-3 blocking peptide or nonsensical peptide. Dye 4',6-diamidino-2-phenylindole (DAPI) labeled nuclei and antibody 6E10 labeled aβ. Scale, 300 μm. N=6 mice per group.
Fig. 4D: FIG. 4C shows the results of statistical analysis of the number of β -amyloid plaques in the hippocampus DG region.
Fig. 4E: FIG. 4C shows the results of statistical analysis of the area of β -amyloid plaques in the hippocampus DG region.
Detailed Description
Embodiments of the present invention will be described in detail below with reference to examples, but it will be understood by those skilled in the art that the following examples are only for illustrating the present invention and should not be construed as limiting the scope of the present invention. The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
In the following examples, 5×fad mice are transgenic model mice for AD disease, which exhibit AD-specific β -amyloid pathological characteristics in the brain; 5×FADA mice were purchased from Jackson Laboratory (Ellsworth, ME, USA), numbered 34840-JAX.
In the following examples, the buffers used for all ThT experiments (thioflavin-T assay) were identical, and the specific formulation was: 50mM sodium phosphate buffer (pH 7.4), 50mM NaCl, 10. Mu.M ThT (a dye) and 0.01% sodium azide.
1-42 Example 1: the expression level of B2M in brain tissue of Alzheimer's disease patient is increased, and the content of Abeta in brain is equal to that of
There is a significant positive correlation in B2M expression levels
Respectively taking brain cortex tissue of AD patients and brain tissue of the same-age non-AD-like dementia control human (obtained from national brain tissue resource library (Zhejiang) and the university of Chinese science and technology neurodegenerative research center, and obtaining the known consent before the brain tissue sample is put in storage), extracting total protein after tissue grinding and RIPA protein lysate cleavage, preparing a sample by BCA concentration measurement, and then performing immunoblotting detection.
The results are shown in fig. 1A to 1B. The results show that B2M protein is significantly elevated in the cerebral cortex of AD patients relative to the control group. The expression level of the presynaptic vesicle protein (syntophysin) detected at the same time in brain tissues of AD patients is obviously lower than that of a control group.
Aβ 1-42 ELISA detection is mainly used for detecting Abeta in brain 1-42 Content of the method canTo A beta in brain tissue per unit weight 1-42 And (5) carrying out quantitative detection. For human brain tissue used in the immunoblotting experiments, abeta is used 1-42 ELISA kit (Thermo Fisher Scientific Co., ltd., product No. KHB 3441) for measuring Abeta 1-42 The content is as follows. The BCA method determines total protein concentration.
Aβ in human brain 1-42 And carrying out Pearson correlation analysis between the content and the relative B2M expression quantity. The results are shown in FIG. 1C. The results show that Abeta in human brain tissue 1-42 Content of a Relative B2M expression level in brain b There is a significant positive correlation between them.
a: and (3) based on a standard substance provided by the kit, performing gradient dilution and then making a standard curve. And (3) diluting the samples, detecting the diluted samples together with a standard substance, detecting the OD value of each sample by using an enzyme-labeled instrument after ELISA reaction is finished, and then calculating the Abeta value of each sample based on a standard curve. The standard curve of the experiment is y=154.21x+5.4233, R 2 =0.9932, y is aβ content, x is OD, 40-fold dilution before control sample detection, 200-fold dilution before AD human brain sample detection.
b: the relative expression results are based on the gel diagram of fig. 1A, and the data are derived from the statistical results of fig. 1B. The average value of the B2M expression quantity (protein band gray value) in the brain of the control group is taken as a basic value, and each sample is compared with the basic value, and the obtained value is the change multiple of the relative expression quantity.
Example 2: increasing B2M content in brain increases beta-amyloid plaque deposition in brain
The hippocampus of the brain of a3 month old 5×fad mouse was cannulated by brain stereotactic technique, and then the mouse was injected with 1 μl (1 μg/μl) of purified B2M protein or PBS every 7 days via the cannula for 2 months. Mice were anesthetized with 5% chloral hydrate after injection, heart perfused with phosphate buffer, brain tissue was taken, fixed overnight in 4% paraformaldehyde, dehydrated with 25% and 30% sucrose solution, brain tissue embedded with OCT, frozen sections, immunofluorescent staining was performed, dye 4',6-diamidino-2-phenylindole (DAPI) labeled nuclei, antibody 6E10 (Biolegend, cat No. 803016) labeled aβ, and images were acquired by laser confocal fluorescent microscopy.
As a result, as shown in fig. 1D to 1F, injection of B2M protein significantly increased the deposition of β -amyloid plaques in the brain compared to injection of PBS.
The results indicate that the level of B2M protein is elevated in the brain of AD mice, and that increasing the B2M content in the brain can further increase the deposition of β -amyloid plaques in the brain of AD mice.
Example 3: B2M and Aβ
1
-42 There is an interaction between
Under in vitro conditions, the purified B2M protein is reacted with purified Abeta 1-42 Proteins were co-incubated, co-immunoprecipitated with anti-Abeta (BioLegend, 6E 10) or anti-B2M (abcam, # 75853) and then analyzed by immunoblotting for the presence of direct interactions in vitro.
The experimental results are shown in fig. 2A to 2B. The results showed that Abeta was co-precipitated either with the anti-Abeta antibody (6E 10) or with the anti-B2M antibody 1-42 And B2M precipitated together.
Further, after the 5×fad mouse brain cortex tissue of 12 months old was taken and subjected to tissue lysis, co-immunoprecipitation was performed with an anti-aβ antibody (6E 10), and then the presence or absence of direct interaction between the two was analyzed by immunoblotting.
The experimental results are shown in fig. 2C. The results show that co-immunoprecipitation with anti-Abeta antibody (6E 10) can precipitate Abeta in vivo 1-42 And B2M precipitated together.
The results show that B2M and Abeta under in vivo and in vitro conditions 1-42 Interaction exists between the two.
Example 4: B2M and Aβ 1 -4 2 Interaction between them can promote Abeta 1 -42 A kind of electronic deviceOligomerization
Sulfur, sulfur and its preparation methodThe element-T is a fluorescent dye which can be combined with beta-sheet-rich protein, and after combination, the fluorescence intensity of the thioflavin T can be enhanced, so that the element-T is an effective index for detecting the formation of fibrinogen. Purified B2M is combined with Abeta in the presence of thioflavin-T 1-42 The two proteins were incubated at 37℃and simultaneously fluorescence values were read with a fluorescence microplate reader every 5min (excitation light λ=448 nm, absorption light λ=488 nm) and continuously detected for 12-14 hours. Drawing a graph based on the change condition of fluorescence value along with time after the experiment is finished, and using the graph in the reaction system for Abeta 1-42 Fibril formation.
The experimental results are shown in fig. 2D. The results show that the B2M protein incubates Abeta 1-42 After that, Aβ can be promoted 1-42 Fibril formation and exhibits a certain concentration dependence.
In addition, the inventors performed thioflavin-T experiments on purified B2M protein alone under the same experimental conditions, since the B2M protein itself also had a certain oligomerization ability.
The experimental results are shown in fig. 2E. The results show that under the same experimental conditions, the B2M protein alone does not oligomerize, does not generate fibrils, and does not interfere with the experimental results in fig. 2D.
The results show that B2M and Abeta 1-42 Interaction between them can promote Abeta 1-42 Is an oligomerization of (a).
1-4 Example 5: the B2M truncated peptide can be used as a blocking peptide for blocking B2M and Abeta 2 Binding, inhibition of B2M-induced Aβ1- 42Oligo(s)Polymerization
To clarify B2M and Abeta 1-42 The amino acid regions where interactions occur, as shown in FIG. 3A, the present inventors truncated the full-length human B2M sequence into 4 small peptides of non-overlapping sequence, designated B2M-1, B2M-2, B2M-3, B2M-4, respectively (see Table 1 for detailed sequences below). The polypeptides in Table 1 were synthesized.
TABLE 1
With B2M truncated peptides and Abeta 1-42 Pre-incubation, small peptides that bind efficiently can block full-length B2M protein from Aβ 1-42 Thereby inhibiting B2M-induced Abeta 1-42 Oligomerization. The inventors separately prepared 10. Mu.M of four truncated peptides and nonsensical control peptide with 10. Mu.M of Abeta 1-42 Preincubation was performed at 37℃for 3 hours, after which 1. Mu.M full-length B2M protein was added for thioflavin-T detection.
The experimental results are shown in FIG. 3B, which shows that only the third B2M-3 truncated peptide can effectively block B2M and Abeta 1-42 Binding, inhibition of B2M-induced Abeta 1-42 Oligomerization.
Further, the present inventors used B2M-3 truncated peptides at different concentrations (5. Mu.M, 10. Mu.M, 20. Mu.M) with 10. Mu.M of Abeta 1-42 Pre-incubation was performed at 37℃for 3 hours, after which 1. Mu.M full length B2M was added and thioflavin-T assay was performed again.
The experimental results are shown in fig. 3C. The results show that the B2M-3 peptide can effectively block B2M induced Abeta 1-42 Oligomerizes and exhibits a certain concentration dependence.
Aβ 1-42 Fibrous oligomers are formed by oligomerization, followed by deposition to form amyloid plaques. Will 10 mu M A beta 1-42 The polypeptide was pre-incubated with 10. Mu. M B2M-3 small peptide at 37℃for 3 hours, then co-incubated with purified 1. Mu.M B2M protein at 37℃for 72 hours, then the samples were spotted on a carbon-coated grid, stained with 1% uranyl acetate, and images were acquired by Hitachi HT-7800 transmission electron microscopy (Hitachi New technology, japan). The experimental results are shown in fig. 3D. The results show that, compared with the control group, the B2M-3 small peptide can effectively inhibit the B2M full-length protein from inducing Abeta after pre-incubation 1-42 Forming fibrous oligomers.
As shown in FIG. 3E, the present inventors further shortened the amino acid sequence to narrow the effective binding range based on B2M-3. The truncated details of B2M-3 are shown in Table 2 below.
TABLE 2
SEQ ID NO: | Naming the name | Sequence(s) |
6 | B2M-3-1 | HSDLSFSKDW |
7 | B2M-3-2 | SFYLLYYTEFTPTEK |
8 | B2M-3-3 | SFYLLYYTE |
After the synthesis of small peptides, the inventors of the present invention truncated three small peptide sequences (B2M-3-1, B2M-3-2 and B2M-3-3) with different concentrations (1. Mu.M, 5. Mu.M, 10. Mu.M) of B2M-3 with 10. Mu.M of Abeta, respectively, using the same experimental method as described above 1-42 Preincubation followed by addition of 1. Mu.M of B2M full-length protein for thioflavin-T detection. The experimental results are shown in fig. 3F to 3H. The results show that both the B2M-3-2 and B2M-3-3 small peptide sequences can effectively inhibit the B2M induced Abeta 1-42 Oligomerizes and has a certain concentration dependence.
The results show that B2M and Abeta 1-42 The interactive amino acid region is mainly located in the third truncated range, and B2M-3 peptide, B2M-3-2 or B2M-3-3 can be used as blocking peptide to effectively inhibit B2M induced Abeta 1-42 Oligomerization, and effective inhibition of B2M-induced β -amyloid plaque formation.
1-42 Example 6: B2M-3 blocking peptides block B2M-induced AβOligo(s) 1-42 Aggregation, thereby inhibiting the neurotoxicity of Abeta
Oligomerized aβ 1-42 Has strong neurotoxicity, and B2M promotes Abeta 1-42 Thereby further enhancing its neurotoxicity. b2M-3 blocking peptide-based inhibition of B2M-induced Abeta 1-42 Oligomerization, it is therefore necessary to investigate whether the B2M-3 blocking peptide is capable of inhibiting B2M-induced oligomerized Abeta 1-42 Is a neurotoxicity of (a).
With 10. Mu.M of B2M-3 peptide or nonsensical control peptide and 10. Mu.M of Abeta, respectively 1-42 Preincubation for 3 hours at 37℃followed by addition of 1. Mu.M full-length B2M protein for a further incubation for 12 hours, yielding two Abeta respectively 1-42 Incubation products with different degrees of oligomerization.
After 2 months old Wild Type (WT) mice were anesthetized, brain tissue was rapidly removed and placed in ice-cold and oxygenated artificial cerebrospinal fluid (ACSF) for cooling, followed by transfer to an oscillating microtome for coronal sectioning, with brain slice thickness of 400 μm. The brain pieces were incubated in 32 ℃ oxygen saturated ACSF for 1 hour, after which they were transferred to room temperature for 1 hour. Oligomerizing Aβ 1-42 The brain slices were incubated for 1.5 hours at room temperature with ACSF diluted to 200 nM. The brain slice was then transferred to the recording tank, the recording electrode was placed in the CA1 region of the Schaffer collateral-commercausal pathway and the stimulation electrode was placed in the CA3 region. Stimulation intensity was 30% of the maximum value of excitatory postsynaptic field potential (field excitatory postsynaptic potential, fEPSP), after 20 minutes of fEPSP baseline stable recording, high Frequency Stimulation (HFS) induced long-term enhancement, LTP (2 bursts of stimulation, each burst containing 100 stimulation pulses, each burst of stimulation spaced 30 seconds apart), for 60 minutes of recording.
The experimental results are shown in fig. 4A to 4B. The results show that pre-incubation with nonsensical peptide resulted in oligomerized aβ compared to brain slices incubated with small peptide alone 1-42 LTP, which significantly impairs the pathway from the CA3 region of the hippocampus to CA1 region Schaffer collateral-comosural of WT mice, was preincubated with B2M-3 blocking peptide to produce Aβ 1-42 Incubation products with different degrees of oligomerization were not clear of LTP from WT miceObvious injury effect.
In summary, A.beta.is pre-incubated with B2M-3 blocking peptide 1-42 Can inhibit B2M from promoting Abeta 1-42 Neurotoxicity resulting from oligomerization.
Example 7: B2M-3 blocking peptides can hinder B2M-induced β -amyloid plaque formation in the mouse brain
Experiments of examples 5-6 demonstrate that B2M-3 blocking peptides can inhibit B2M-induced Abeta under in vitro conditions 1-42 Oligomerization, thereby attenuating the oligomeric Abeta 1-42 Is a neurotoxicity of (a). To further verify the inhibitory effect of B2M-3 blocking peptide on B2M-induced β -amyloid plaque formation in vivo, the present inventors embedded a cannula into the hippocampal region of the brain of B2M humanized 5×fad mice by brain stereotactic technique, followed by weekly injections of 1 μl (5 μg/μl) of nonsensical peptide or B2M-3 blocking peptide, respectively, into the left and right hippocampus of the mice via the cannula for 2 months. After injection, mice were anesthetized with 5% chloral hydrate, perfused with phosphate buffer, brain tissue was taken, fixed overnight in 4% paraformaldehyde, dehydrated with 25% and 30% sucrose solution, brain tissue was embedded with OCT, frozen sections, immunofluorescent staining was performed, dye 4',6-diamidino-2-phenylindole (DAPI) -labeled nuclei, antibody 6E10 (Biolegend, cat 803016) -labeled aβ 1-42 The image was acquired by confocal laser fluorescence microscopy.
The experimental results are shown in fig. 4C to 4E. The results show that injection of B2M-3 blocking peptide significantly reduced the deposition of β -amyloid plaques in the brain compared to injection of nonsensical peptide.
In summary, the B2M-3 blocking peptide was able to effectively inhibit B2M-induced deposition of β -amyloid plaques in the brain of 5×fad mice.
Although specific embodiments of the invention have been described in detail, those skilled in the art will appreciate. Numerous modifications and substitutions of details are possible in light of all the teachings disclosed, and such modifications are contemplated as falling within the scope of the present invention. The full scope of the invention is given by the appended claims and any equivalents thereof.
SEQUENCE LISTING
<110> Xiamen university
<120> beta 2-microglobulin blocking peptides, pharmaceutical compositions and uses thereof
<130> IDC220074
<160> 15
<170> PatentIn version 3.5
<210> 1
<211> 31
<212> PRT
<213> Artificial Sequence
<220>
<223> B2M-1
<400> 1
His His His His His His Ile Gln Arg Thr Pro Lys Ile Gln Val Tyr
1 5 10 15
Ser Arg His Pro Ala Glu Asn Gly Lys Ser Asn Phe Leu Asn Cys
20 25 30
<210> 2
<211> 31
<212> PRT
<213> Artificial Sequence
<220>
<223> B2M-2
<400> 2
His His His His His His Tyr Val Ser Gly Phe His Pro Ser Asp Ile
1 5 10 15
Glu Val Asp Leu Leu Lys Asn Gly Glu Arg Ile Glu Lys Val Glu
20 25 30
<210> 3
<211> 31
<212> PRT
<213> Artificial Sequence
<220>
<223> B2M-3
<400> 3
His His His His His His His Ser Asp Leu Ser Phe Ser Lys Asp Trp
1 5 10 15
Ser Phe Tyr Leu Leu Tyr Tyr Thr Glu Phe Thr Pro Thr Glu Lys
20 25 30
<210> 4
<211> 30
<212> PRT
<213> Artificial Sequence
<220>
<223> B2M-4
<400> 4
His His His His His His Asp Glu Tyr Ala Cys Arg Val Asn His Val
1 5 10 15
Thr Leu Ser Gln Pro Lys Ile Val Lys Trp Asp Arg Asp Met
20 25 30
<210> 5
<211> 31
<212> PRT
<213> Artificial Sequence
<220>
<223> Non-sense
<400> 5
His His His His His His Gln Phe Lys Ser Ile Lys Asn Pro Gln His
1 5 10 15
Glu Val Gly Ala Ile Asn Arg Cys Arg Asn Pro Leu Thr Tyr Ser
20 25 30
<210> 6
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> B2M-3-1
<400> 6
His Ser Asp Leu Ser Phe Ser Lys Asp Trp
1 5 10
<210> 7
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<223> B2M-3-2
<400> 7
Ser Phe Tyr Leu Leu Tyr Tyr Thr Glu Phe Thr Pro Thr Glu Lys
1 5 10 15
<210> 8
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> B2M-3-3
<400> 8
Ser Phe Tyr Leu Leu Tyr Tyr Thr Glu
1 5
<210> 9
<211> 119
<212> PRT
<213> Artificial Sequence
<220>
<223> human B2M
<400> 9
Met Ser Arg Ser Val Ala Leu Ala Val Leu Ala Leu Leu Ser Leu Ser
1 5 10 15
Gly Leu Glu Ala Ile Gln Arg Thr Pro Lys Ile Gln Val Tyr Ser Arg
20 25 30
His Pro Ala Glu Asn Gly Lys Ser Asn Phe Leu Asn Cys Tyr Val Ser
35 40 45
Gly Phe His Pro Ser Asp Ile Glu Val Asp Leu Leu Lys Asn Gly Glu
50 55 60
Arg Ile Glu Lys Val Glu His Ser Asp Leu Ser Phe Ser Lys Asp Trp
65 70 75 80
Ser Phe Tyr Leu Leu Tyr Tyr Thr Glu Phe Thr Pro Thr Glu Lys Asp
85 90 95
Glu Tyr Ala Cys Arg Val Asn His Val Thr Leu Ser Gln Pro Lys Ile
100 105 110
Val Lys Trp Asp Arg Asp Met
115
<210> 10
<211> 42
<212> PRT
<213> Artificial Sequence
<220>
<223> human Aβ1-42
<400> 10
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
1 5 10 15
Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
20 25 30
Gly Leu Met Val Gly Gly Val Val Ile Ala
35 40
<210> 11
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> truncated fragment of B2M
<400> 11
Ser Phe Tyr Leu Leu Tyr Tyr Thr Glu Phe Thr Pro Thr Glu
1 5 10
<210> 12
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> truncated fragment of B2M
<400> 12
Ser Phe Tyr Leu Leu Tyr Tyr Thr Glu Phe Thr Pro Thr
1 5 10
<210> 13
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> truncated fragment of B2M
<400> 13
Ser Phe Tyr Leu Leu Tyr Tyr Thr Glu Phe Thr Pro
1 5 10
<210> 14
<211> 11
<212> PRT
<213> Artificial Sequence
<220>
<223> truncated fragment of B2M
<400> 14
Ser Phe Tyr Leu Leu Tyr Tyr Thr Glu Phe Thr
1 5 10
<210> 15
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> truncated fragment of B2M
<400> 15
Ser Phe Tyr Leu Leu Tyr Tyr Thr Glu Phe
1 5 10
Claims (10)
1. An isolated polypeptide which is a polypeptide as set forth in SEQ ID NO. 3 or a truncated fragment of a polypeptide as set forth in SEQ ID NO. 3, wherein the truncated fragment comprises a polypeptide as set forth in SEQ ID NO. 8.
2. The isolated polypeptide of claim 1, wherein the truncated fragment does not comprise the 6 histidines at the N-terminus of the polypeptide shown in SEQ ID No. 3.
3. The isolated polypeptide of claim 1 or 2, which is a polypeptide represented by any one of SEQ ID NOs 7-8 or 11-15.
4. An isolated polynucleotide encoding the isolated polypeptide of any one of claims 1 to 3.
5. A recombinant expression vector comprising the isolated polynucleotide of claim 4.
6. A transformed cell comprising the recombinant expression vector of claim 5.
7. A pharmaceutical composition comprising the isolated polypeptide of any one of claims 1 to 3.
8. The pharmaceutical composition of claim 7, further comprising one or more pharmaceutically acceptable excipients.
9. Use of an isolated polypeptide according to any one of claims 1 to 3 for the manufacture of a medicament for the treatment or prophylaxis of alzheimer's disease.
10. Use of an isolated polypeptide according to any one of claims 1 to 3 in the preparation of a medicament for:
inhibition of B2M-induced Abeta 1-42 Oligomerizing agents, agents inhibiting B2M-induced formation of beta-amyloid plaques or inhibiting aβ 1-42 Is a neurotoxic drug.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210609077.3A CN117186199A (en) | 2022-05-31 | 2022-05-31 | Beta 2-microglobulin blocking peptide, pharmaceutical composition and application thereof |
PCT/CN2023/097492 WO2023232083A1 (en) | 2022-05-31 | 2023-05-31 | Beta 2-microglobulin blocking peptide, and pharmaceutical composition and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210609077.3A CN117186199A (en) | 2022-05-31 | 2022-05-31 | Beta 2-microglobulin blocking peptide, pharmaceutical composition and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117186199A true CN117186199A (en) | 2023-12-08 |
Family
ID=88998414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210609077.3A Pending CN117186199A (en) | 2022-05-31 | 2022-05-31 | Beta 2-microglobulin blocking peptide, pharmaceutical composition and application thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117186199A (en) |
WO (1) | WO2023232083A1 (en) |
-
2022
- 2022-05-31 CN CN202210609077.3A patent/CN117186199A/en active Pending
-
2023
- 2023-05-31 WO PCT/CN2023/097492 patent/WO2023232083A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2023232083A1 (en) | 2023-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bressler et al. | cDNA cloning and chromosome mapping of the human Fe 65 gene: interaction of the conserved cytoplasmic domains of the human beta-amyloid precursor protein and its homologues with the mouse Fe 65 protein | |
US7897568B2 (en) | Compositions for treatment of cancer | |
US7745571B2 (en) | Peptide inhibitors of IASPP | |
US20070248599A1 (en) | Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor | |
JP2001501972A (en) | Amyloid beta protein (globular assembly and its use) | |
JP4776544B2 (en) | Mutant amyloid protein | |
CN109776665A (en) | Alzheimer disease new mutation, its surely turn cell model and medical usage | |
Southwell et al. | Antibody therapy in neurodegenerative disease | |
US20110104715A1 (en) | Cytotoxic peptides and peptidomimetics based thereon, and methods for use thereof | |
HUE028729T2 (en) | Compositions for prevention and treatment of neurodegenerative diseases | |
US20060263781A1 (en) | Regulation of cell surface proteins | |
CN117186199A (en) | Beta 2-microglobulin blocking peptide, pharmaceutical composition and application thereof | |
CN115475247B (en) | Pharmaceutical use of beta 2-microglobulin or inhibitor thereof | |
JP6659050B2 (en) | Method for diagnosing or treating neurological disorders by P75 ECD and / or P75 | |
CN113711045A (en) | Method for screening compound for treating or preventing polyQ-related neurodegenerative disease | |
CN112763718A (en) | Method for screening compound for treating or preventing polyQ-related neurodegenerative disease | |
WO2023246847A1 (en) | B2m-glun1 blocking peptide, and pharmaceutical composition and use thereof | |
US20060239988A1 (en) | Neuronal regeneration and compound administration methods | |
AU2009227824A1 (en) | Cytotoxic peptides and peptidomimetics based thereon, and methods for use thereof | |
Chan | An Investigation of the Roles of FE65 Interactors in Neurite Outgrowth and APP Processing | |
CN111679082A (en) | Method for screening compound for treating or preventing polyQ-related neurodegenerative disease | |
JP2021534826A (en) | Peptide therapeutics and their use for the treatment of cancer | |
JPWO2004001038A1 (en) | Novel genes and proteins involved in neuronalization of cells or tissues and use thereof | |
AU2004222677A1 (en) | Regulation of cell surface proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |